{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:47:48Z","timestamp":1787942868349,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bone.2021.116004","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T05:41:52Z","timestamp":1620711712000},"page":"116004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Burosumab treatment for fibrous dysplasia"],"prefix":"10.1016","volume":"150","author":[{"given":"Anne","family":"Gladding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Szymczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany A.","family":"Auble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116004_bb0005","doi-asserted-by":"crossref","unstructured":"Boyce AM, Collins MT. Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of galpha s activation. Endocr Rev 2020;41(2) doi: https:\/\/doi.org\/10.1210\/endrev\/bnz011[published Online First: Epub Date]|.","DOI":"10.1210\/endrev\/bnz011"},{"key":"10.1016\/j.bone.2021.116004_bb0010","doi-asserted-by":"crossref","unstructured":"Riminucci M, Liu B, Corsi A, et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol 1999;187(2):249\u201358 doi: 10.1002\/(sici)1096-9896(199901)187:2<249::Aid-path222>3.0.Co;2-j[published Online First: Epub Date]|.","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J"},{"key":"10.1016\/j.bone.2021.116004_bb0015","doi-asserted-by":"crossref","unstructured":"Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112(5):683\u201392 doi: https:\/\/doi.org\/10.1172\/jci18399[published Online First: Epub Date]|.","DOI":"10.1172\/JCI18399"},{"key":"10.1016\/j.bone.2021.116004_bb0020","doi-asserted-by":"crossref","unstructured":"Bhattacharyya N, Wiench M, Dumitrescu C, et al. Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 2012;27(5):1132\u201341 doi: https:\/\/doi.org\/10.1002\/jbmr.1546[published Online First: Epub Date]|.","DOI":"10.1002\/jbmr.1546"},{"key":"10.1016\/j.bone.2021.116004_bb0025","doi-asserted-by":"crossref","unstructured":"Boyce AM, Bhattacharyya N, Collins MT. Fibrous dysplasia and fibroblast growth factor-23 regulation. Curr Osteoporos Rep 2013;11(2):65\u201371 doi: https:\/\/doi.org\/10.1007\/s11914-013-0144-5[published Online First: Epub Date]|.","DOI":"10.1007\/s11914-013-0144-5"},{"key":"10.1016\/j.bone.2021.116004_bb0030","doi-asserted-by":"crossref","unstructured":"Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 2012;7 Suppl 1(Suppl 1):S4 doi: https:\/\/doi.org\/10.1186\/1750-1172-7-s1-s4[published Online First: Epub Date]|.","DOI":"10.1186\/1750-1172-7-S1-S4"},{"key":"10.1016\/j.bone.2021.116004_bb0035","doi-asserted-by":"crossref","unstructured":"Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 2014;3(1):R13\u201330 doi: https:\/\/doi.org\/10.1530\/ec-13-0103[published Online First: Epub Date]|.","DOI":"10.1530\/EC-13-0103"},{"key":"10.1016\/j.bone.2021.116004_bb0040","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 2018;378(21):1987\u201398 doi: https:\/\/doi.org\/10.1056\/NEJMoa1714641[published Online First: Epub Date]|.","DOI":"10.1056\/NEJMoa1714641"},{"key":"10.1016\/j.bone.2021.116004_bb0045","doi-asserted-by":"crossref","unstructured":"Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393(10189):2416\u201327 doi: https:\/\/doi.org\/10.1016\/s0140-6736(19)30654-3[published Online First: Epub Date]|.","DOI":"10.1016\/S0140-6736(19)30654-3"},{"key":"10.1016\/j.bone.2021.116004_bb0050","doi-asserted-by":"crossref","unstructured":"Insogna KL, Briot K, Imel EA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 2018;33(8):1383\u201393 doi: https:\/\/doi.org\/10.1002\/jbmr.3475[published Online First: Epub Date]|.","DOI":"10.1002\/jbmr.3475"},{"key":"10.1016\/j.bone.2021.116004_bb0055","doi-asserted-by":"crossref","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, et al. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 2020 doi: https:\/\/doi.org\/10.1002\/jbmr.4233[published Online First: Epub Date]|.","DOI":"10.1002\/jbmr.4233"},{"key":"10.1016\/j.bone.2021.116004_bb0060","unstructured":"Crysvita [package insert]. Novato, CA: Ultragenyx Pharmaceuticals Inc. 2020."},{"key":"10.1016\/j.bone.2021.116004_bb0065","doi-asserted-by":"crossref","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis 2019;14(1):139 doi: https:\/\/doi.org\/10.1186\/s13023-019-1102-9[published Online First: Epub Date]|.","DOI":"10.1186\/s13023-019-1102-9"},{"key":"10.1016\/j.bone.2021.116004_bb0070","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am. J. Kidney Dis. 2005;46.","DOI":"10.1053\/j.ajkd.2005.07.028"},{"key":"10.1016\/j.bone.2021.116004_bb0075","doi-asserted-by":"crossref","unstructured":"Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74(11):1385\u201393 doi: https:\/\/doi.org\/10.1038\/ki.2008.356[published Online First: Epub Date]|.","DOI":"10.1038\/ki.2008.356"},{"key":"10.1016\/j.bone.2021.116004_bb0080","doi-asserted-by":"crossref","unstructured":"Leet AI, Chebli C, Kushner H, et al. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 2004;19(4):571\u20137 doi: https:\/\/doi.org\/10.1359\/jbmr.0301262[published Online First: Epub Date]|.","DOI":"10.1359\/JBMR.0301262"},{"key":"10.1016\/j.bone.2021.116004_bb0085","doi-asserted-by":"crossref","unstructured":"Berglund JA, Tella SH, Tuthill KF, et al. Scoliosis in fibrous dysplasia\/McCune-Albright syndrome: factors associated with curve progression and effects of bisphosphonates. J Bone Miner Res 2018;33(9):1641\u201348 doi: https:\/\/doi.org\/10.1002\/jbmr.3446[published Online First: Epub Date]|.","DOI":"10.1002\/jbmr.3446"},{"key":"10.1016\/j.bone.2021.116004_bb0090","doi-asserted-by":"crossref","unstructured":"Pan KS, Heiss JD, Brown SM, Collins MT, Boyce AM. Chiari I malformation and basilar invagination in fibrous dysplasia: prevalence, mechanisms, and clinical implications. J Bone Miner Res 2018;33(11):1990\u201398 doi: https:\/\/doi.org\/10.1002\/jbmr.3531[published Online First: Epub Date]|.","DOI":"10.1002\/jbmr.3531"},{"issue":"7","key":"10.1016\/j.bone.2021.116004_bb0095","first-page":"A4874","article-title":"Treatment of hypophosphataemic rickets in children remains a challenge","volume":"61","author":"Nielsen","year":"2014","journal-title":"Dan. Med. J."},{"key":"10.1016\/j.bone.2021.116004_bb0100","doi-asserted-by":"crossref","unstructured":"Robinson C, Estrada A, Zaheer A, et al. Clinical and radiographic gastrointestinal abnormalities in McCune-Albright syndrome. J Clin Endocrinol Metab 2018;103(11):4293\u2013303 doi: https:\/\/doi.org\/10.1210\/jc.2018-01022[published Online First: Epub Date]|.","DOI":"10.1210\/jc.2018-01022"},{"key":"10.1016\/j.bone.2021.116004_bb0105","doi-asserted-by":"crossref","unstructured":"Wood LD, No\u00eb M, Hackeng W, et al. Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Arch 2017;470(4):391\u2013400 doi: https:\/\/doi.org\/10.1007\/s00428-017-2086-2[published Online First: Epub Date]|.","DOI":"10.1007\/s00428-017-2086-2"},{"key":"10.1016\/j.bone.2021.116004_bb0110","doi-asserted-by":"crossref","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int 2021;108(1):128\u201342 doi: https:\/\/doi.org\/10.1007\/s00223-020-00691-6[published Online First: Epub Date]|.","DOI":"10.1007\/s00223-020-00691-6"},{"key":"10.1016\/j.bone.2021.116004_bb0115","doi-asserted-by":"crossref","unstructured":"Florenzano P, Pan KS, Brown SM, et al. Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone. J Bone Miner Res 2019;34(4):653\u201360 doi: https:\/\/doi.org\/10.1002\/jbmr.3649[published Online First: Epub Date]|.","DOI":"10.1002\/jbmr.3649"},{"key":"10.1016\/j.bone.2021.116004_bb0120","doi-asserted-by":"crossref","unstructured":"Paul SM, Gabor LR, Rudzinski S, et al. Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia. Bone 2014;60:41\u20137 doi: https:\/\/doi.org\/10.1016\/j.bone.2013.11.022[published Online First: Epub Date]|.","DOI":"10.1016\/j.bone.2013.11.022"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:57:23Z","timestamp":1757613443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":24,"alternative-id":["S8756328221001666"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116004","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burosumab treatment for fibrous dysplasia","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116004"}}